
Body weight (g)
PND
Healthy control (n=9)
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.6 mg/kg (n=22)

FIG. 1


Body weight (g)
Healthy control (n=9)
Tamoxifen-induced control (n=22)

FIG. 2


Body weight (g)
30
20
10
0
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 3


Total kidney weight (g)
2.5
2.0
1.5
1.0
0.5
0.0
<0.0001
Healthy control (n=9)
Tamoxifen-induced control (n=22)

FIG. 4


Total kidney weight (g)
2.5
2.0
1.5
1.0
0.5
0.0
Tamoxifen-induced control (n=22)
Tolvaptan 6.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 5


KW/BW*100 (%)
15
10
5
0
<0.0001
Healthy control (n=9)
Tamoxifen-induced control (n=22)

FIG. 6


15
10
5
0
KW/BW*100 (%)
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 7


30
20
10
0
Urea level (mmol/l)
<0.0001
Healthy control (n=9)
Tamoxifen-induced control (n=22)

FIG. 8


0.0299
30
20
10
0
Urea level (mmol/l)
Tamoxifen-induced control (n=22)
Teriflunomide 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 9


100
50
0
Percent survival
0
20
40
60
Days after treatment
Healthy control (n=9)
Tamoxifen-induced control (n=22)
p=0.0010

FIG. 10


100
50
0
Percent survival
0
20
40
60
Days after treatment
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 11


1.5
1.0
0.5
0.0
KV/BW*100 (%)
<0.0001
Healthy control (n=9)
Tamoxifen-induced control (n=22)

FIG. 12


KV/BW*100 (%)
Tamoxifen-induced control (n=22)
Solvent 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 13


KV/BW*100 (%)
<0.0001
Healthy control (n=9)
Tamoxifen-induced control (n=22)

FIG. 14


KV/BW*100 (%)
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=20)
Compound 2 0.1 mg/kg (n=23)
Compound 2 0.5 mg/kg (n=22)

FIG. 15


KV/BW*100 (%)
<0.0001
Healthy control (n=9)
Tamoxifen-induced control (n=22)

FIG. 16


Tamoxifen-induced control (n=17)
Tolvaptan 0.1% (n=18)
Compound 2 0.1 mg/kg (n=20)
Compound 2 0.5 mg/kg (n=18)

FIG. 17


Cystic index (%)
0
10
20
30
40
50
Tamoxifen-induced control (n=21)
Tolvaptan 0.1% (n=23)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 18


Cystic grade
0
2
4
6
Tamoxifen-induced control (n=22)
Telvagliflon 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 19


0.0445
Tubular dilatation (grade)
0
1
2
3
4
Tamoxifen-induced control (n=22)
Telvagliflon 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 20


0.0039
0.0475
Tubular casts (grade)
2.5
2.0
1.5
1.0
0.5
0.0
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 21


Tubular inflammation (grade)
2.0
1.5
1.0
0.5
0.0
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 22


Glomerular atrophy (grade)
0
1
2
3
4
5
Tamoxifen-induced control (n=22)
Tolvaptan 0.1% (n=22)
Compound 2 0.1 mg/kg (n=22)
Compound 2 0.5 mg/kg (n=22)

FIG. 23


eGFR Mean±SE Change from Baseline (Screening)
6.00
4.00
2.00
0.00
-2.00
-4.00
-6.00
-8.00
-10.00
-12.00
-14.00
Placebo
50 mcg
150 mcg
300 mcg
Compound 2 PO QD x 14 days
One day before the last dose

FIG. 24